Table 2.
Data summary of all pooled articles
| Characteristic | Value |
|---|---|
|
| |
| Cohort size (n) | 67 |
| Median age, range (yrs) | 31, 9–78 |
| gender | |
| Male | 40 (59.7%) |
| Female | 27 (40.3%) |
| Most common locations (n = 55) | N (%) |
|
| |
| Anterior skull base | 19/55 (34.5%) |
| Middle skull base | 29/55 (52.7%) |
| Posterior skull base | 7/55 (12.7 %) |
| Most common involved structures (n = 55) | N (%) |
|
| |
| Sphenoid bone | 15 (22.4%) |
| Sphenoid sinus | 8 (12%) |
| Temporal bone | 6 (9%) |
| others | 29 (43.4%) |
| Most common presenting symptoms (n = 51) | N (%) |
|
| |
| Headache | 18(27%) |
| Exophthalmos | 12(18%) |
| Diplopia | 5(10.4%) |
| Others | 16(46.6%) |
| Type of etiology (n = 67) | N (%) |
|
| |
| Primary osteosarcoma | 46 (68.4%) |
| Radiation induced osteosarcoma | 17 (25.4%) |
| Metastatic osteosarcoma | 4 (6%) |
| Metastases (n = 5) | N (%) |
|
| |
| Primary osteosarcoma (n = 2) | Parietal bone and liver; shoulder bones |
| Radiation induced osteosarcoma (n = 1) | Pulmonary |
| Metastatic osteosarcoma (n = 2) | Multiple facial bones; lung and maxilla |
| Histopathological type (n = 21) | N (%) |
|
| |
| Osteoblastic | 9 (42.9%) |
| Chondroblastic | 7 (33.3%) |
| Telangiectatic | 4 (19%) |
| Fibroblastic | 1 (4.8%) |
| Management | N (%) |
|
| |
| Surgery | 60 (89.6%) |
| Of reported surgical details (n = 53) | |
| Complete resection | 29 (54.7%) |
| Partial resection | 24 (45. 3%) |
| Chemotherapy | 44 (65.7 %) |
| Radiotherapy, | 34 (50.7%) |
| Median dose, IQR (cGy, n = 7) | 5000, 4500–5500 |
| Outcome | N (%) |
|
| |
| Median PFS, range (mos) (n = 31) | 12, 0.2–143 |
| Median OS, Range (mos) (n = 63) | 12, 1.5–66 |
| Recurrence (n/%) | 17 (25.4%) |
| Disease progression (n/%) | 13 (19.4%) |
| Status (n= 63) | N (%) |
|
| |
| Alive (n/%) | 30 (48%) |
| Dead (n/%) | 33, (52%) |